Amicogen Decides 12.1% Dilutive Third-Party Allotment for Operating Funds with Expected Change of Largest Shareholder

Amicogen has decided a third-party allotment capital increase to raise approximately 10 billion KRW for operating funds.
The company will issue 8,554,319 new shares representing a 12.1% dilution relative to current outstanding shares at an issue price of 1,169 KRW, a 10% discount to the benchmark price of 1,298 KRW and a 22.7% discount to the current market price of 1,513 KRW.
The allotted party is YK BioNova Holdings which will become the largest shareholder after payment and the new shares are subject to a one-year lock-up.
This holder is a small holding company with total assets of 10 billion KRW and no revenue or net income as of end-2025 raising significant governance concerns.
The use of proceeds is limited to working capital without any expansionary or transformational purpose reducing potential upside for existing shareholders.
[AI Summary]Amicogen's highly dilutive capital increase at a steep discount creates short-term stock price downside risk while the opaque nature of the new largest shareholder and lack of growth-oriented use of funds warrant cautious investor sentiment.